Equine Herpesvirus-4 (EHV-4)

Equine Herpesvirus-4 (EHV-4) is a highly prevalent respiratory pathogen affecting horses worldwide, representing one of the most common causes of viral upper respiratory tract disease in equines. This DNA virus belongs to the Alphaherpesvirinae subfamily and is closely related to Equine Herpesvirus-1 (EHV-1), though it typically causes milder disease limited primarily to the respiratory system. EHV-4 is endemic in horse populations globally, with most horses experiencing infection during their first years of life and developing partial immunity that moderates subsequent infections.

The virus affects horses of all ages but causes the most significant clinical disease in young horses, particularly weanlings and yearlings experiencing their first exposure. Foals protected by maternal antibodies may not show clinical signs upon initial exposure but remain susceptible once passive immunity wanes. Training facilities, sale barns, show grounds, and racing stables with frequent horse movement experience regular EHV-4 circulation. The virus spreads rapidly through susceptible populations, often causing outbreaks that sideline multiple horses simultaneously.

While EHV-4 is generally considered less severe than its relative EHV-1, the economic impact on equine operations remains substantial. Respiratory infections interrupt training schedules, delay racing careers, and necessitate withdrawal from competitions. Outbreaks at sales or shows can result in facility-wide quarantines and event cancellations. Secondary bacterial infections may complicate recovery and extend downtime. Performance horses require complete respiratory recovery before returning to athletic work, which may take several weeks following infection.

The good news regarding EHV-4 is that infection is typically self-limiting in healthy horses, with most cases resolving within two to three weeks with appropriate supportive care. Unlike EHV-1, neurological disease associated with EHV-4 is extremely rare, though occasional abortion cases have been documented. Vaccination is available and recommended for horses at risk, though protection is incomplete and requires regular boosters. Understanding EHV-4 transmission, implementing appropriate biosecurity measures, and providing supportive care when infection occurs enables horse owners and managers to minimize the impact of this common respiratory pathogen.

The causative agent of EHV-4 infection is the equine herpesvirus type 4, a double-stranded DNA virus transmitted primarily through respiratory secretions. Direct contact between horses provides the most efficient transmission route, with infectious nasal discharge containing high viral loads during acute infection. Aerosol transmission over short distances occurs when infected horses cough or sneeze. Indirect transmission via contaminated equipment, feed containers, water sources, and handlers' hands and clothing also facilitates spread between horses that do not have direct contact.

No genetic or breed predisposition exists for EHV-4 infection, as all horses are susceptible to this ubiquitous pathogen. However, immunological status significantly influences disease expression. Horses with no previous exposure develop more severe clinical signs than those with existing immunity from prior infection or vaccination. Young horses are most commonly affected clinically because they have limited immunological experience with the virus. Older horses typically have developed partial immunity through repeated exposure, resulting in milder or subclinical infections.

Environmental and management factors heavily influence EHV-4 transmission dynamics. High-density housing, poor ventilation, and close horse-to-horse contact facilitate respiratory pathogen spread. Facilities that regularly introduce new horses from multiple sources experience more frequent virus circulation. Stress factors including transportation, competition, training intensity, dietary changes, and concurrent disease increase both susceptibility to infection and severity of clinical signs. Cold weather housing conditions often bring horses into closer contact, contributing to seasonal outbreak patterns.

Risk factors for EHV-4 clinical disease include young age, stress, immunosuppression, and high exposure doses. Weanlings experiencing the stress of separation from their dams while mixing with new horses face particularly high risk. Yearlings entering training facilities encounter numerous pathogens in high-density environments. Horses receiving immunosuppressive medications, those with concurrent illness, and pregnant mares experiencing late-gestation stress may develop more severe disease. The quantity of virus inhaled during exposure influences disease severity, with higher doses typically causing more pronounced clinical signs.

The pathophysiology of EHV-4 involves initial viral replication in the epithelial cells lining the upper respiratory tract following inhalation of infectious particles. The virus replicates locally in the nasal passages, pharynx, and upper trachea, causing cell death, inflammation, and the characteristic respiratory symptoms. Unlike EHV-1, EHV-4 rarely establishes significant cell-associated viremia, which explains its typical restriction to respiratory disease without systemic manifestations. Following acute infection, the virus establishes latency in lymphoid tissue, persisting for the life of the horse with potential for reactivation during stress. Reactivation events may cause recrudescent disease or serve as sources of transmission to susceptible horses.

Early warning signs of EHV-4 infection are often subtle and easily overlooked, particularly in adult horses with partial immunity. Initial indicators may include slight depression, mild reduction in appetite, and low-grade fever that may not be detected without routine temperature monitoring. Horses may appear slightly less energetic than normal or show reduced enthusiasm during feeding. Because horses instinctively mask illness as a survival mechanism, owners and caretakers must develop keen observational skills to detect these subtle changes. Regular temperature monitoring, especially during respiratory disease season or following new horse introductions, helps identify infections early.

Common symptoms of established EHV-4 respiratory infection include fever ranging from 102°F to 105°F, clear to mucopurulent nasal discharge, coughing, and enlarged submandibular lymph nodes. The fever pattern is often biphasic, with an initial spike followed by temporary normalization and a second elevation several days later. Nasal discharge typically begins as clear and serous before becoming thicker, more opaque, and sometimes yellow-tinged if secondary bacterial infection develops. Coughing may be sporadic or frequent, often worsening with exercise or dust exposure.

Behavioral changes associated with EHV-4 infection reflect general malaise from systemic inflammation. Affected horses commonly show reduced appetite, decreased water intake, and lethargy. They may stand quietly with a lowered head, showing less interest in their surroundings than usual. Social interactions with herdmates typically decrease. Performance horses may refuse or resist work, showing decreased willingness and stamina. Young horses in group housing may separate themselves from penmates, seeking isolation rather than social contact.

Physical signs beyond the primary respiratory involvement include conjunctivitis with ocular discharge in some cases, mild limb edema occasionally, and a generally dull hair coat appearance in affected horses. Auscultation of the throat and trachea may reveal increased respiratory sounds, while lung sounds typically remain clear in uncomplicated cases. Weight loss may occur during acute illness due to reduced feed intake and increased metabolic demands from fever. Dehydration can develop if horses reduce water consumption significantly.

Symptom progression in uncomplicated EHV-4 follows a predictable pattern in most cases. Fever typically persists for three to seven days before resolving. Nasal discharge may continue for up to two weeks, gradually transitioning from mucopurulent back to clear before ceasing. Coughing often persists longest, sometimes continuing for three weeks or more as damaged respiratory epithelium regenerates. Lymph node enlargement gradually resolves over one to two weeks. Full appetite and energy return as fever subsides, though complete respiratory healing requires additional time.

Emergency symptoms requiring immediate veterinary attention include high fever above 104°F that persists despite initial treatment, difficulty breathing or severely increased respiratory rate, complete anorexia lasting more than 24 hours, severe depression or weakness, and any neurological abnormalities. While neurological disease is rare with EHV-4, it has been reported occasionally and warrants urgent investigation. Pneumonia complicating EHV-4 infection requires aggressive treatment. Any unusual signs in young foals warrant immediate veterinary evaluation due to their limited physiological reserves and rapid deterioration potential.

Physical examination provides initial diagnostic direction in suspected EHV-4 cases. Veterinarians assess vital signs including temperature, heart rate, respiratory rate, and mucous membrane color. Elevated temperature combined with nasal discharge and submandibular lymph node enlargement strongly suggests viral respiratory infection. Auscultation of the upper airways may reveal increased sounds from inflammation and mucus accumulation. Careful evaluation rules out lower respiratory involvement that might indicate secondary pneumonia. Assessment of hydration status and overall condition guides supportive care recommendations.

Diagnostic tests for definitive EHV-4 identification include polymerase chain reaction (PCR) testing of nasal swab samples, which provides rapid, sensitive detection of viral DNA. PCR can differentiate between EHV-4 and the closely related EHV-1, which is clinically important given their different disease potentials. Virus isolation from nasal secretions in cell culture provides definitive diagnosis but requires specialized laboratory facilities and takes longer than molecular testing. Serological testing can demonstrate rising antibody titers between acute and convalescent blood samples, though interpretation is complicated by vaccination history and previous natural exposure.

Advanced diagnostics are rarely necessary for straightforward EHV-4 respiratory cases but may be indicated in complicated or atypical presentations. Complete blood count during acute infection often shows lymphopenia reflecting viral infection of lymphocytes. Thoracic ultrasonography or radiography is warranted if secondary pneumonia is suspected based on auscultation findings, increased respiratory effort, or failure to improve with routine supportive care. Endoscopy of the upper airways may reveal inflammation, mucus accumulation, or structural abnormalities contributing to clinical signs. Transtracheal wash with cytology and culture helps identify bacterial pathogens in suspected secondary infections.

Differential diagnosis of EHV-4 respiratory infection includes other common equine respiratory pathogens. Equine influenza causes similar clinical signs but often with more severe fever and coughing. Strangles (Streptococcus equi infection) presents with marked lymph node enlargement that may abscess. Equine herpesvirus-1 causes identical respiratory signs but has additional systemic disease potential. Equine viral arteritis produces respiratory symptoms along with limb edema and abortion. Bacterial bronchopneumonia from various agents may resemble viral infection complicated by secondary bacterial invasion. Inflammatory airway disease or exercise-induced pulmonary hemorrhage should be considered in performance horses with coughing and poor performance. Accurate diagnosis guides treatment decisions and biosecurity measures.

Emergency and immediate treatment considerations for EHV-4 focus on isolation of affected horses and initiation of supportive care rather than specific antiviral therapy. Any horse with fever and respiratory signs should be separated from healthy horses pending diagnostic confirmation. Dedicated equipment, protective clothing for handlers, and foot baths at isolation area boundaries help prevent spread to healthy animals. Temperature monitoring of in-contact horses should begin immediately to detect additional cases early. Environmental modifications including dust reduction and improved ventilation support respiratory healing.

Medical management of EHV-4 is primarily supportive, as the infection is self-limiting in most healthy horses. Non-steroidal anti-inflammatory drugs (NSAIDs) including flunixin meglumine or phenylbutazone reduce fever and improve comfort, often restoring appetite and attitude. While specific antiviral therapy has limited proven efficacy against EHV-4, some veterinarians prescribe valacyclovir in severe cases or outbreak situations. Antibiotics are not indicated for uncomplicated viral respiratory infection but should be administered if secondary bacterial pneumonia develops, guided by culture and sensitivity results when possible.

Surgical intervention is not applicable for EHV-4 treatment. However, severely affected horses may require placement of intravenous catheters for fluid therapy if dehydration develops from reduced water intake and fever. In rare cases of severe upper respiratory inflammation causing breathing difficulty, temporary tracheostomy might be considered, though this is extremely unusual with EHV-4 infection.

Supportive care forms the foundation of EHV-4 treatment and significantly influences recovery speed and completeness. Ensuring adequate hydration through offering fresh, palatable water and potentially adding electrolytes or flavoring helps combat dehydration from fever and reduced intake. Nutritional support through highly palatable feeds maintains gastrointestinal function and provides energy for immune responses. Rest from training and competition allows the respiratory tract to heal without additional stress. Clean, well-ventilated environments with minimal dust reduce airway irritation. Soaked hay or steamed forage decreases particulate inhalation during respiratory recovery.

Rehabilitation and return to work should be gradual following EHV-4 recovery. Horses should remain at rest until fever has resolved for at least 48 to 72 hours and appetite has normalized. Gradual reintroduction of light exercise can begin once respiratory signs have substantially resolved, typically two to three weeks after disease onset. Coughing during exercise indicates incomplete healing, and workout intensity should be reduced or suspended until coughing resolves. Performance horses may require four to six weeks of rehabilitation before returning to full work, as premature return to intense exercise may trigger recurrence or complications.

Treatment decision factors include disease severity, individual horse value and use, availability of isolation facilities, and financial considerations. Mild cases in healthy adult horses often require minimal intervention beyond rest and basic supportive care. Young horses, immunocompromised individuals, or horses developing complications warrant more aggressive treatment and monitoring. Outbreak situations may justify early treatment of in-contact horses or broader antiviral use despite limited evidence for efficacy. Owners should work with their veterinarian to develop treatment plans appropriate to individual circumstances while implementing biosecurity measures protecting other horses.

Recovery timeline for uncomplicated EHV-4 respiratory infection follows a predictable course in most horses. Fever typically resolves within three to seven days of onset, with attitude and appetite improving as temperature normalizes. Nasal discharge may persist for up to two weeks before clearing completely. Coughing often continues for two to three weeks as the damaged respiratory epithelium regenerates. Full return to normal activity typically occurs three to four weeks after disease onset, though some horses require longer recovery periods. Complete restoration of the respiratory tract's protective mechanisms may take several weeks beyond clinical recovery.

Post-treatment care and monitoring focus on ensuring complete resolution and preventing complications. Daily temperature monitoring should continue until readings remain normal for several days. Observing for coughing, nasal discharge, and appetite provides indicators of ongoing recovery. Gradual reintroduction of exercise allows assessment of respiratory function under stress. Any recurrence of fever, worsening respiratory signs, or development of new symptoms warrants veterinary reevaluation. Horses should be isolated from susceptible populations until viral shedding has ceased, typically two to three weeks after symptom resolution.

Prognosis factors influencing EHV-4 recovery include age, overall health status, severity of initial infection, and development of complications. Healthy adult horses with uncomplicated infections have excellent prognoses for complete recovery. Young horses with less developed immune systems may have more prolonged illness but generally recover fully. Secondary bacterial pneumonia significantly extends recovery time and may cause residual lung damage affecting future athletic performance. Concurrent illness, immunosuppression, or severe stress negatively impacts recovery. Attentive nursing care and appropriate environmental management improve outcomes across all severity levels.

Long-term soundness outlook following EHV-4 is generally excellent for horses with uncomplicated infections. Most horses return to full athletic function without residual effects. The damaged respiratory epithelium regenerates completely in typical cases, restoring normal mucociliary clearance and airway function. Horses that develop secondary bacterial pneumonia may experience some degree of persistent inflammatory airway disease affecting performance. Similar to EHV-1, horses remain latent carriers of EHV-4 following infection, with potential for reactivation during stress. This carrier status has minimal practical implications for most horses, as EHV-4 circulates widely in horse populations and causes relatively mild disease.

Management practices form the cornerstone of EHV-4 prevention in equine facilities. Biosecurity protocols including quarantine of new arrivals for 14 to 21 days allow detection of incubating respiratory infections before exposure to resident horses. Grouping horses by age and use reduces mixing of animals with different exposure histories and immune statuses. Dedicated equipment for different horse groups prevents indirect transmission. Regular handwashing or glove changes between handling horses interrupts transmission chains. Staff education regarding disease recognition and biosecurity compliance ensures consistent protocol adherence.

Nutritional factors support immune function and disease resistance. Providing balanced nutrition appropriate for age, workload, and physiological status maintains optimal body condition and immune competence. Adequate protein supports antibody production and tissue repair. Vitamin E, selenium, and other antioxidants support cellular immune function. Avoiding nutritional stress from inadequate or excessive feeding maintains horses in conditions that support disease resistance. Young horses in training require particular nutritional attention as they face high disease exposure while still developing adult immune competence.

Exercise and conditioning influence susceptibility to EHV-4 through effects on stress and immune function. Horses maintained in appropriate fitness experience less physiological stress from training and competition than those that are overworked or unconditioned for their demands. Gradual conditioning programs allow physiological adaptation without creating immunosuppression from excessive stress. Allowing recovery time following intense efforts, long transportation, or competitions helps maintain immune vigilance. Young horses entering training programs benefit from gradual workload increases that allow concurrent immune system maturation.

Environmental factors significantly affect respiratory pathogen transmission. Well-ventilated barns reduce airborne viral concentrations and respiratory irritation from ammonia and dust. Outdoor housing or generous turnout time decreases exposure compared to confined indoor environments. Avoiding overcrowding reduces both stress and direct transmission opportunities. Temperature extremes stress respiratory defense mechanisms, so appropriate shelter from severe weather helps maintain health. Dust control through arena watering, bedding selection, and soaked or steamed hay reduces airway irritation that may increase disease susceptibility.

Vaccination against EHV-4 is available as both monovalent and combination products that often include EHV-1. Vaccination is recommended for horses at elevated risk including young horses in training, show horses that travel frequently, and horses at facilities with regular new introductions. Primary vaccination series typically involves two or three doses followed by boosters every six months for horses at high risk. While vaccines do not prevent infection or eliminate viral shedding, they reduce disease severity and duration in vaccinated horses. Vaccination should be viewed as one component of comprehensive prevention strategy alongside biosecurity and management practices. Owners should discuss vaccination protocols with their veterinarian based on individual horse risk factors and regional disease prevalence.

Daily management adjustments for horses recovering from EHV-4 or residing at facilities with circulating virus focus on supporting recovery while minimizing transmission. Temperature monitoring should continue for all horses during and after outbreaks, as early detection of new cases allows prompt isolation and treatment. Feeding and watering routines should emphasize individual containers rather than shared sources to reduce indirect transmission. Staff handling recovered horses before moving to healthy horses should change gloves or wash hands to prevent carriage. Consistent daily routines reduce stress, which can trigger viral reactivation in carrier horses.

Housing and turnout considerations during EHV-4 recovery and outbreak management balance welfare needs with transmission prevention. Recovering horses benefit from turnout in individual paddocks where fresh air and light exercise support healing without exposing susceptible horses. Group housing should be suspended for recovered horses until veterinary clearance regarding viral shedding status. Barn ventilation should be maximized to reduce airborne viral concentrations. Isolation facilities should have separate airspace from main populations when possible. Gradual reintegration with healthy horses can proceed once recovery is complete and shedding has ceased.

Exercise modifications during and after EHV-4 infection prioritize respiratory healing over training progression. Horses with active infection should receive complete rest from athletic work until fever resolves and symptoms substantially improve. Light hand walking can begin once acute signs subside, allowing gentle activity without respiratory stress. Gradual return to ridden work proceeds based on absence of coughing and normal respiratory effort during exercise. Training intensity increases slowly over two to four weeks, monitoring for any recurrence of respiratory signs. Dusty arenas should be watered or avoided during early return to work.

Monitoring and ongoing care for horses recovering from EHV-4 ensures complete resolution and detects any complications promptly. Daily observation for coughing, nasal discharge, appetite, and attitude continues throughout recovery. Periodic veterinary reassessment may be indicated for horses with prolonged symptoms or suspected complications. Respiratory rate and effort during rest and light exercise provide indicators of healing progress. Weight monitoring ensures adequate nutrition during recovery. Any setbacks including fever recurrence, worsening cough, or new symptoms warrant immediate veterinary consultation.

Quality of life and use considerations following EHV-4 are generally minimal, as most horses recover completely without lasting effects. Performance horses may require schedule adjustments to accommodate recovery time, potentially missing planned competitions. Training timelines for young horses may need revision if infection causes significant setbacks. Horses that develop secondary complications may require extended rehabilitation and careful assessment before returning to previous activity levels. Breeding stallions and mares should recover fully before resuming breeding activities to minimize stress and prevent transmission to breeding partners.

Equine Herpesvirus-4 affects all horse breeds equally, as susceptibility is determined by immune status and exposure rather than genetic factors. Thoroughbreds, Quarter Horses, Warmbloods, Arabians, and all other breeds face equivalent infection risk when exposed to the virus. Ponies, miniature horses, donkeys, and mules are also susceptible. No breed-specific genetic factors provide protection against EHV-4 infection or modify disease severity. The universal susceptibility reflects the virus's adaptation to exploit conserved equine respiratory physiology present across all breeds.

Use and discipline considerations influence EHV-4 exposure risk significantly more than breed factors. Young horses entering training programs face high exposure in environments where numerous animals from different origins congregate. Racehorses at training centers encounter regular virus circulation due to high population turnover. Show horses traveling to multiple events have repeated exposure opportunities. Sale yearlings experience high stress combined with mixing of animals from many sources. In contrast, pleasure horses remaining on private properties with stable populations have reduced exposure probability. Competition schedules, training environments, and transportation frequency are more predictive of EHV-4 risk than breed affiliation.

Genetic testing for EHV-4 susceptibility does not exist, as no inherited factors determining disease risk have been identified. Breeding recommendations focus on management to reduce disease transmission rather than genetic selection. Pregnant mares should be vaccinated against EHV-1/4 and separated from horses likely to introduce infection. Young stock can be vaccinated prior to weaning or sale to provide some protection during high-risk transition periods. Breeding operations benefit from stable population groups with controlled introduction of outside horses during breeding season. Selection for overall immune competence through maintaining healthy body condition and appropriate nutrition indirectly supports disease resistance across all breeds.

Commonly co-occurring conditions with EHV-4 include secondary bacterial respiratory infections that may complicate viral disease. Streptococcus equi subspecies zooepidemicus, Pasteurella species, and other opportunistic bacteria may cause secondary pneumonia when viral infection compromises respiratory defenses. Inflammatory airway disease may develop or worsen following EHV-4 infection, with persistent coughing and exercise intolerance continuing after viral clearance. Concurrent stressors including poor nutrition, parasitism, or other concurrent infections increase disease severity and complication risk.

Conditions with similar symptoms that must be differentiated from EHV-4 include other common respiratory pathogens. Equine influenza produces similar fever, coughing, and nasal discharge, typically with more severe and abrupt onset. Strangles causes respiratory signs along with characteristic abscess formation in submandibular and retropharyngeal lymph nodes. Equine herpesvirus-1 produces identical respiratory symptoms but carries risk for neurological disease and abortion. Equine viral arteritis causes respiratory illness with additional systemic signs including limb edema and conjunctivitis. Bacterial bronchopneumonia may present similarly, especially when secondary to viral infection. Accurate diagnosis through laboratory testing guides appropriate treatment and biosecurity decisions.

Potential complications of EHV-4 infection, while generally uncommon in healthy horses, include secondary bacterial pneumonia, prolonged inflammatory airway disease, and rare neurological or reproductive manifestations. Secondary pneumonia requires extended antibiotic treatment and may cause permanent lung damage affecting future athletic performance. Inflammatory airway disease persisting after infection can create ongoing exercise intolerance and coughing requiring anti-inflammatory therapy. While EHV-4 primarily causes respiratory disease, isolated cases of abortion and extremely rare neurological disease have been attributed to this virus. Horses remain latent carriers following infection, with implications for future reactivation and transmission during stress periods.